FDA Inspection 1209420 — Sinopharm Weiqida Pharmaceutical Co. Ltd.
The FDA completed an inspection of Sinopharm Weiqida Pharmaceutical Co. Ltd. on May 25, 2023 in Datong. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions were found but do not meet the threshold for regulatory action). Product area: Drugs.
Inspection Details
- Classification
- Voluntary Action Indicated (VAI) (VAI)
- End Date
- May 25, 2023
- Fiscal Year
- 2023
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Datong (China)